Ghrelin vs IGF-1 DES
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Ghrelin
Endogenous 28-amino acid peptide secreted primarily by the stomach that functions as both the primary hunger signal and a potent growth hormone secretagogue. The n-octanoyl modification at Ser-3 (acylated form) is required for GHS-R1a receptor binding and GH-stimulating activity. Understanding ghrelin explains the mechanism behind the entire GHRP class of research peptides.
Full profileIGF-1 DES
IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.
Full profile| Ghrelin | IGF-1 DES | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | GHRL, growth hormone-releasing peptide endogenous, ghrelinergic peptide, acyl ghrelin | Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1 |
| Evidence | Investigational (in trials) | Research-stage |
| Dosing range | 0.5mcg/kg–2mcg/kg mcg/kg, IV or SC bolus; endogenous levels peak pre-meal | 50mcg–150mcg mcg, 1–2x daily, preferably post-workout |
| Administration | Intravenous (research), Subcutaneous injection | Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect) |
| Key side effects | Appetite stimulation, Transient hyperglycemia, Water retention, GH pulse stimulation | Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Ghrelin is investigational (in trials), while IGF-1 DES is research-stage.
- Administration: Ghrelin — Intravenous (research), Subcutaneous injection; IGF-1 DES — Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect).
- Dosing units differ: Ghrelin is dosed in mcg/kg, IGF-1 DES in mcg — they operate at different scales.
- Frequency: Ghrelin is typically IV or SC bolus; endogenous levels peak pre-meal; IGF-1 DES is 1–2x daily, preferably post-workout.
How each works
Ghrelin
Ghrelin was discovered in 1999 as the endogenous ligand for the GHS-R1a receptor. Its acylated form activates GH release from the pituitary, stimulates appetite via NPY/AgRP hypothalamic neurons, and modulates energy homeostasis and fat storage. The des-acyl form (majority of circulating ghrelin) lacks GHS-R1a activity but has independent cardiovascular and cellular effects.
IGF-1 DES
The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.